doi: 10.1121/1.3158859
Disclosures: Shuhei Yamamoto: Nothing to Disclose, Takahiro Kodama: Chugai Pharmaceuticals: Speaking and Teaching, Astrazeneca: Speaking and Teaching, Eisai Co Ltd: Speaking and Teaching, Kazuki Maesaka: Nothing to Disclose, Akifumi Kuwano: Nothing to Disclose, kenta Motomura: Nothing to Disclose, Kumiko Shirai: Nothing to Disclose, Akira Doi: Nothing to Disclose, Kazuhiro Murai: Nothing to Disclose, Yuki Tahata: Nothing to Disclose, Yoshinobu Saito: Nothing to Disclose, Hayato Hikita: Nothing to Disclose, Tomohide Tatsumi: Nothing to Disclose, Tetsuo Takehara: Nothing to Disclose 1946 LIPOPHILIC STATIN INCREASES SENSITIVITY FOR LENVATINIB BY SUPPRESSING YAP/TAZ IN HEPATOCELLULAR CARCINOMA CELL LINES AND PATIENT-DERIVED ORGANOIDS Jae Seung Lee 1 Kyung Joo Cho 2 Hye Jung Park 2 Hye Won Lee 1 Mi Na Kim 1 Beom Kyung Kim 1 Do Young Kim 1 Sang Hoon Ahn 1 Jun Yong Park 1 , 1 Yonsei University College of Medicine, 2 Severance Hospital Background: Elevated expression of the transcription factors Yes-associated protein (YAP) and its paralogue, transcriptional co-activator with PDZ-binding motif (TAZ), contributes to drug resistance and adverse prognosis in patients with hepatocellular carcinoma (HCC)
Its important to understand that these guidelines are in place to prioritize safety and effectiveness
To accommodate the anticipated heterogeneity due to variations in population characteristics and study durations, random effects analysis models were employed
However, several clinical considerations may influence selection: Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use any GLP-1 receptor agonist
Many people experience significant weight loss, reduced appetite, and improved metabolic health
